Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
_↗ globenewswire.com
News Image

Advanced Biomed announced the launch of its A+PerfusC™ system, a compact, all-in-one perfusion 3D cell culture platform. Designed to replicate human physiological conditions in vitro, the system integrates automated perfusion with environmental control, allowing for up to 12 days of continuous, hands-free cell culture. announced the launch of its A+PerfusC™ system, a compact, all-in-one perfusion 3D cell culture platform. Designed to replicate human physiological conditions in vitro, the system integrates automated perfusion with environmental control, allowing for up to 12 days of continuous, hands-free cell culture.

This automated process reduces the risk of human error and contamination while ensuring uniform nutrient delivery and waste removal. This is a significant improvement over traditional static cell culture, which often suffers from uneven nutrient distribution and waste buildup that can compromise cell viability and the accuracy of research.

The A+PerfusC™ platform promotes the formation of organoids and spheroids, which are more complex and realistic models of human tissue, thereby enhancing cell viability and the predictability of drug responses. The system is highly scalable and versatile, offering eight independent channels per plate, each capable of supporting up to 600 tumor spheroids, and can be easily integrated with microscopy platforms for real-time observation.

Potential applications for this technology are broad, including personalized oncology, regenerative medicine, and stem cell research. Advanced Biomed has completed internal testing and validation of the system and its consumables, and is currently focused on mass production development to prepare for commercialization. The company also plans to enhance the platform with high-throughput capabilities and AI-driven analytics to further accelerate tumor profiling and advance personalized medicine. The launch of this system positions Advanced Biomed to capitalize on the growing global 3D cell culture market, which is projected to exceed $4.71 billion by 2030.

Log In
Sign Up